CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis

Haematologica. 2015 Jul;100(7):e257-60. doi: 10.3324/haematol.2014.119602. Epub 2015 Feb 20.
No abstract available

Keywords: CD127+ ILCs; acute myeloid leukemia; dysregulated; innate lymphoid cells; treatment naive.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Case-Control Studies
  • Cell Lineage / drug effects
  • Cell Lineage / immunology*
  • Cytarabine / therapeutic use
  • Daunorubicin / therapeutic use
  • Female
  • Gene Expression
  • Humans
  • Immunity, Innate
  • Immunophenotyping
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / immunology
  • Interleukin-7 Receptor alpha Subunit / genetics
  • Interleukin-7 Receptor alpha Subunit / immunology*
  • Interleukins / biosynthesis
  • Interleukins / immunology
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / pathology*
  • Leukemia, Myeloid, Acute / therapy
  • Lymphocytes / classification
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Lymphocytes / pathology*
  • Male
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antineoplastic Agents
  • Interleukin-7 Receptor alpha Subunit
  • Interleukins
  • Tumor Necrosis Factor-alpha
  • Cytarabine
  • Interferon-gamma
  • Daunorubicin